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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that is
genetically associated with MHC class II molecules that
contain the shared epitope. This shared epitope is a con-
served amino acid motif (QK/RRAA) found within the third
hypervariable region of the DRβ chains of DRB1*0101,
DRB1*0404, and DRB1*0401. Notably, HLA-DR mole-
cules not associated with RA (e.g. DRB1*0402) contain
oppositely charged amino acids at some of these posi-
tions (DERAA). Because this shared epitope is found
within the peptide-binding groove of these MHC class II
molecules, it may confer the ability to selectively bind
arthritogenic peptide sequences for presentation to auto-
reactive T cells.
The participation of CD4+ T cells in initiating and perpetu-
ating the inflammatory response seen in RA has been well
documented [1]. The protein/peptide targets recognized
by these T cells, however, have not been conclusively iden-
tified. Studies in mouse models have shown that immuniza-
tion with joint derived proteins such as type II collagen (CII)
and the human proteoglycan aggrecan (hAG) can induce
an RA-like disease that is MHC class II restricted [2–4].
Advances in determining human MHC class II restricted
APC = antigen-presenting cell; CII = type II collagen; DR4 = DRB1*0401 MHC class II molecule; hAG = human aggrecan; HBsAg = hepatitis B
surface antigen; IFN = interferon; IL = interleukin; mAb = monoclonal antibody; RA = rheumatoid arthritis; TCR = T-cell receptor; Th = T-helper
(cell).
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Abstract
The HLA-DRB1*0401 MHC class II molecule (DR4) is
genetically associated with rheumatoid arthritis. It has been
proposed that this MHC class II molecule participates in
disease pathogenesis by presenting arthritogenic endogenous
or exogenous peptides to CD4+ T cells, leading to their
activation and resulting in an inflammatory response within the
synovium. In order to better understand DR4 restricted T cell
activation, we analyzed the candidate arthritogenic antigens
type II collagen, human aggrecan, and the hepatitis B surface
antigen for T-cell epitopes using a predictive model for
determining peptide–DR4 affinity. We also applied this model to
determine whether cross-reactive T-cell epitopes can be
predicted based on known MHC–peptide–TCR interactions.
Using the HLA-DR4-IE transgenic mouse, we showed that both
T-cell proliferation and Th1 cytokine production (IFN-γ) correlate
with the predicted affinity of a peptide for DR4. In addition, we
provide evidence that TCR recognition of a peptide–DR4
complex is highly specific in that similar antigenic peptide
sequences, containing identical amino acids at TCR contact
positions, do not activate the same population of T cells.
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T-cell epitopes from CII have been made using
DRβ1*0401 (DR4) transgenic mice [5–8]. Using overlap-
ping peptide sequences, a single dominant epitope has
been characterized that has a relatively high affinity for DR4
[7,8]. Although overlapping peptide sequences have con-
ventionally been used to determine T-cell epitopes, quanti-
tative MHC binding motifs that predict peptide–
DRB1*0401 affinity have proven to be a valuable tool
[6,9,10]. These predictive models have shown that specific
amino acid side-chains within a bound peptide contribute
to DR4 binding affinity, depending on their location within
the binding groove [11–13]. Models such as these have
defined a number of DR4 restricted T-cell epitopes, and
may aid in determining an arthritogenic peptide.
The foregoing may also help to identify molecular mimics
of endogenous self-antigens that have been proposed as
triggers of autoimmunity [14]. Thus, a T-cell immune
response to an exogenous microbial peptide could prime
a cross-reactive response to an autoantigen [15–17]. In
the case of RA, identifying exogenous and endogenous
antigens that are predicted to bind to DR4 with high affin-
ity, and present similarly to the TCR, may provide insight
into how this disease could be triggered or perpetuated.
We and others have reported on the development of RA
soon after vaccination with the recombinant hepatitis B
surface antigen (HBsAg) [18–20], and we have also
shown that many of these patients express MHC contain-
ing the shared epitope. These observations have led us to
hypothesize that peptides from HBsAg may activate
autoreactive T cells under DR4 restriction.
In the present study, we used a predictive model for HLA-
DRB1*0401–peptide affinity [11] to: determine the
number of potential T-cell epitopes within the candidate
endogenous arthritogenic antigens CII and hAG, and the
exogenous antigen HBsAg; determine whether a correla-
tion exists between peptide–DR4 affinity and T-cell activa-
tion; and explore molecular mimicry between HBsAg and
the endogenous cartilage-derived antigen hAG. Using
HLA-DR4-IE transgenic mice [21], we show that a strong
correlation exists between the predicted affinity of a
peptide for HLA-DRB1*0401 and its ability to induce the
proliferation of DR4 restricted T cells with a Th1 cytokine
profile. We also show that a cross-reactive DR4 restricted
T-cell response can not be predicted on the basis of
peptide–TCR interactions alone.
Materials and methods
Animals
HLA-DR4-IE transgenic, murine MHC class II deficient
mice were used in these experiments [21]. Briefly, these
mice express a chimeric MHC class II molecule composed
of human antigen binding domains (HLA-DRA and HLA-
DRB1*0401), whereas the remaining domains are mouse
derived (IEd-α2 and IEd-β2). These mice were bred in a
barrier facility (John P Robarts Barrier Facility, London,
Ontario, Canada) and maintained at a conventional animal
housing facility (Animal Care and Veterinary Services, Uni-
versity of Western Ontario, London, Ontario, Canada).
Mice used in these experiments (male and female) were
6–10 weeks old.
Peptides
Peptides used in these experiments were synthesized
using a solid phase peptide synthesizer and F-moc technol-
ogy (Milligen 9050; Procyon Biopharma Inc., London,
Ontario, Canada). Peptides used in these experiments
(Table 1) include sequences from human CII (amino acids
261–273 and 316–333), hAG (amino acids 280–292 and
1786–1798), and the HBsAg (amino acids 16–33,
94–106, and 159–171). Peptides from HBsAg 16–33
that have been altered to assess cross-reactivity are
HBsAg L23A and HBsAg L23A/T28R (Table 1 and Fig. 5).
Immunizations
DR4-IE transgenic mice were immunized intradermally at
the interior side of both hind legs with 100 µl peptide
(1 µg/µl) emulsified in complete Freund’s adjuvant (1:1
volume ratio). Complete Freund’s adjuvant consisted of
4 mg/ml heat-killed H37RA Mycobacterium tuberculosis
suspended in incomplete Freund’s adjuvant (both from
Difco Laboratories, Detroit, MI, USA). After 10 days, mice
were killed and their draining lymph nodes were removed
for in vitro proliferation and cytokine assays.
Proliferation assay
Cell suspensions were prepared from the draining lymph
nodes and resuspended in RPMI 1640 supplemented with
10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml
streptomycin, 2 mmol L-glutamine and 50 µmol 2-ME (all
from Gibco BRL, Burlington, Ontario, Canada). Cells were
then cultured in Falcon 96-well U-bottom tissue culture
plates (Beckton Dickinson, Franklin Lakes, NJ, USA) at a
concentration of 4 × 105 cells/well. Cell cultures contained
peptides at concentrations of 0 µg/ml, 1 µg/ml, 10 µg/ml,
or 50 µg/ml. Cultures were incubated for 4 days at 37°C in
5% humidified carbon dioxide. Eighteen hours before
culture termination, 2 µCi of [3H] thymidine (ICN Biomed-
icals, Montreal, Quebec, Canada) was added to each well.
Cells were harvested onto glass fiber filters (Wallac, Turku,
Finland) and radioactivity was determined using a Wallac
1450 Microbeta liquid scintillation counter and UltraTerm 3
software. Experiments were conducted in triplicate and
data are expressed as average stimulation index (decay
counts per min of experimental sample/counts per min of
control sample).
Cytokine detection
Lymph node cells (4 × 105) from peptide immunized DR4-IE
transgenic mice were cultured either in the presence or
absence of peptide (10 µg/ml), as described underArthritis Research and Therapy    Vol 5 No 1 Hill et al.
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Proliferation assay (see above). After 48 and 72 hours,
supernatants were collected and pooled from triplicate
wells for detecting IL-4 and IFN-γ production, respectively.
Cytokine concentrations were determined using commer-
cially available OptEIATM mouse IFN-γ and IL-4 capture
enzyme-linked immunosorbent assay kits (Pharmingen;
Mississauga, Ontario, Canada) according to the manufac-
turer’s instructions. Purified antimouse IFN-γ or IL-4 mAb
were used for cytokine capture. Recombinant mouse IFN-γ
or IL-4 were used as standards, and biotinylated antimouse
IFN-γ or IL-4 mAb were used as detecting reagents. All
experiments were conducted in duplicate and data repre-
sents average antigen-specific cytokine production
(cytokine production of control samples plus 2 SD were
subtracted from the peptide-specific cytokine production).
Generation and characterization of T-cell lines
DR4-IE transgenic mice were immunized with the peptide
hAG 280–292 or HBsAg 16–33 (100 µg/mouse), as
described under Immunizations (see above). Ten days
later, draining lymph nodes were removed and a cell sus-
pension was prepared in RPMI 1640 supplemented
medium. Cells were cultured at a concentration of 4 × 106
in 24-well plates (Costar; Cambridge, MA, USA) and stim-
ulated with the respective antigen (10 µg/ml). After 7 days
of incubation at 37°C in 5% humidified carbon dioxide,
supernatants were removed from cultures and fresh
medium containing recombinant IL-2 (0.01 µg/ml; R&D
systems, Minneapolis, MN, USA) was added to the wells.
Seven days after the addition of IL-2, supernatants were
removed again and cells were restimulated with 3 × 106
irradiated (2500 rads) syngeneic spleen cells (antigen-
presenting cells [APCs]) and specific peptide antigen
(10 µg/ml). These T-cell lines were maintained by
repeated alternating cycles of weekly restimulation with
IL-2 or peptide and irradiated APCs. T-cell line reactivity to
peptide antigen was confirmed (after 6–10 weeks of
repeated cycles) by proliferation and cytokine production.
In order to test T-cell line proliferation and IFN-γ produc-
tion, 1 × 105 T cells/well were cultured in the presence or
absence of peptide (10 µg/ml) and 4 × 105 irradiated
APCs/well. [3H]-thymidine incorporation and IFN-γ pro-
duction were measured as described above (see Prolifera-
tion assay and Cytokine detection).
Results
Analysis of candidate arthritogenic antigens for DR4
binding
In order to assess antigens for predicted immunogenicity in
the context of DR4, we utilized the model of Hammer et al.
[11] for predicting peptide–MHC affinity. This model defines
the relative affinity of an amino acid for a specific DR4
binding pocket. The sum of all amino acid contributions from
each of the nine DR4 binding pockets gives a numeric
binding score for a peptide’s affinity. Binding scores of more
than 2 are predicted to have a high affinity for DR4.
Using this predictive model, we analyzed human CII, the
first globular domain and second chondroitin sulfate
binding domain from hAG, and the HBsAg, all of which
have been implicated in RA pathogenesis [2,18,22,23].
As seen in Fig. 1, the first globular domain and the second
chondroitin sulfate binding domain of hAG, as well as the
HBsAg contain, multiple peptide sequences that are pre-
dicted to bind to DR4 with high affinity. CII does not
contain a peptide sequence that reaches a binding score
in excess of 2; however, the highest scoring peptide (1.5)
was 263–271, which has been shown to be immunodomi-
nant in the context of DR4 [6,7].
T-cell proliferative response to predicted DR4 restricted
epitopes
Peptides with a range of predicted affinities were tested
for their ability to activate T cells from DR4-IE transgenic
mice, in order to confirm that this model identifies epitopes
that are immunogenic. The selected peptides and their
binding scores are indicated in Table 1. Briefly, two pep-
tides were chosen from CII, two from hAG, and three from
HBsAg, with binding scores ranging from –1.1 to +5.4.
DR4-IE transgenic mice were immunized with each of the
peptides and T-cell proliferative responses were measured
10 days later.
Peptide sequences with binding scores below 0 did not
elicit a proliferative response in these transgenic mice;
however, a dose-dependent response was seen for pep-
tides with binding scores greater than 0 (Fig. 2). When the
proliferative response to peptides was compared with
their binding score, a strong correlation was seen
(Fig. 3a). Thus, although peptides with binding scores
greater than 2 are indeed immunogenic in these DR4
transgenic mice, some peptides that fall below this range
also have this property.
Cytokine response to predicted DR4 restricted T-cell
epitopes
Because cytokine production by activated T cells is
believed to play an integral role in the inflammatory
response in RA, and because peptide–MHC affinity may
dictate to some extent whether a Th1 or Th2 response is
elicited [24], we tested the ability of the selected peptides
to induce either IFN-γ or IL-4 production. Once again
peptide immunized DR4-IE transgenic mice were used to
measure these responses. IFN-γ production was seen in
lymph node cultures stimulated with CII 261–273, hAG
280–292, hAG 1786–1798, and HBsAg 16–33 (Fig. 4).
IL-4 production, however, was undetectable at any
peptide concentration used. The predicted low affinity
peptides CII 316–333, HBsAg 94–106, and HBsAg
159–171 did not elicit IFN-γ or IL-4 production. Similar to
proliferative responses, a strong correlation was seen
between the production of IFN-γ and the peptide binding
score (Fig. 3b).Available online http://arthritis-research.com/content/5/1/R40
R43
Figure 1
DR4 binding score analysis of the endogenous antigens (a) human type II collagen (hCII), the (b) first globular domain (G1) and the (c) second
chondroitin sulfate binding domain (CS-2) of human aggrecan (hAG), and (d) the exogenous antigen hepatitis B surface antigen (HBsAg). Binding
scores were calculated according to the method employed by Hammer et al. [11].
hAG G1 domain
Binding score distribution
< - 6 - 5- 4- 3- 2- 100 . 11 2 3 4 5> 6
N
u
m
b
e
r
 
o
f
 
p
e
p
t
i
d
e
s
0
5
10
15
20
25
30
35
hCII 
Binding score distribution
< - 6 - 5 - 4 - 3 - 2 - 10 0 . 1 12345 > 6
N
u
m
b
e
r
 
o
f
 
p
e
p
t
i
d
e
s
0
5
10
15
20
25
30
35
(a) (b)
(c) (d)
HBsAg
Binding score distribution
< - 6 - 5- 4- 3- 2- 100 . 11 2 3 4 5> 6
N
u
m
b
e
r
 
o
f
 
p
e
p
t
i
d
e
s
0
5
10
15
20
25
30
35
hAG CS-2 domain
Binding score distribution
< 6 - 5 - 4 - 3 - 2 - 10 0 . 1 12345 > 6
N
u
m
b
e
r
 
o
f
 
p
e
p
t
i
d
e
s
0
5
10
15
20
25
30
35
Table 1
Peptide sequences and predicted DR4 binding scores
DR4 binding 
Peptide source Sequence score
hCII (261–273) AGFKGEQGPKGEP 1.5
hCII (316–333) GFPFQDFLAFPKGAPGER –0.5
hAG (280–292) AGWLADRSVRYPI 4.1
hAG (1786–1798) GAYYGSGTPSSFP 5.4
HBsAg (16–33) YQAGFFLLTRILTIPQSLD 3.1
HBsAg (94–106) LLVLLDYQGMLPV –1.1
HBsAg (159–171) AKYLWEWASVRFS 0.8
HBsAg L23A GFFLATRILTIPQ 2.1
HBsAg L23A/T28R GFFLATRILRIPQ 2.3
Peptide sequences are shown from amino-terminus to carboxyl-
terminus. Underlined amino acids indicate the predicted residues that
interact with the MHC binding groove from P1 to P9. DR4 binding
scores were calculated according to the method of Hammer et al. [11].
hCII, human type II collagen; hAG, human aggrecan; HBsAg, hepatitis
B surface antigen.
Figure 2
Dose-dependent proliferative response to predicted DR4 binding
peptides in DR4-IE transgenic mice. DR4-IE transgenic mice were
immunized with the indicated peptides and 10 days later their lymph
node cells (4 × 105) were challenged in vitro with the same peptide.
Data represents the average proliferative response ± SEM of three
mice for each peptide tested. This is representative of three
independent experiments with similar results. CII, type II collagen; hAG,
human aggrecan; HBsAg, hepatitis B surface antigen.
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HBsAg 159-171DR4 restricted cross-reactivity
Because genetic factors alone cannot fully account for
RA, environmental influences may affect disease expres-
sion. Molecular mimicry between microbial antigens and
endogenous proteins is an intriguing explanation for trig-
gering disease in genetically susceptible individuals.
Because a specific joint derived autoantigen has not been
identified in RA, it is difficult to address this hypothesis
conclusively. However, using the predictive model for
peptide–DR4 affinity we explored the general properties
of CD4+ T cells to recognize two unique DR4 restricted
candidate arthritogenic peptide antigens.
Elucidation of the crystal structure of the trimolecular
complex (MHC–peptide–TCR) has shown that certain
amino acids from the antigenic peptides are buried within
the MHC binding groove whereas others point away from
this groove and make contacts with the TCR [25–28].
These TCR contact positions are found at P2, P3, P5, and
P8. In light of this, we reasoned that two unique peptides,
predicted to bind to DR4 with high affinity and with similar
amino acids at TCR contact positions, might activate the
same population of T cells.
We chose to study the hAG 280–292 and HBsAg 16–33
peptides because these peptides both activate T cells in
DR4-IE transgenic mice and share the same residues at
the P2 and P5 positions. Because amino acids at the TCR
contact positions P3 and P8 differ between the two pep-
tides, we also synthesized altered peptides based on the
HBsAg sequence. As shown in Fig. 5, the HBsAg L23A
peptide has the P3 amino acid substituted by the P3
amino acid from hAG 280–292, and the HBsAg
L23A/T28R peptide has both the P3 and the P8 amino
acid substitutions. The immunogenicity of the two altered
peptides was confirmed by T-cell proliferation in DR4-IE
transgenic mice (Fig. 6).
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Figure 3
The ability of a peptide to induce proliferation and IFN-γ production in DR4-IE transgenic mice correlates with the DR4 binding score. 
(a) Correlation between DR4 binding score and T-cell proliferation. Data were compiled from experiments described in Fig. 2 using a peptide
concentration of 10 µg/ml and represent the average stimulation index ± SEM. (b) Correlation between DR4 binding score and IFN-γ production.
Data were compiled from experiments described in Fig. 4 using a peptide concentration of 10 µg/ml and represent the average IFN-γ
response ± SD. Correlation coefficients are indicated as r2.
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Figure 4
IFN-γ production in response to predicted DR4 binding peptides in
DR4-IE transgenic mice. DR4-IE transgenic mice were immunized with
the indicated peptides and 10 days later their lymph node cells (4 ×
105) were challenged in vitro with the same peptide (10 µg/ml). The
peptides human type II collagen (hCII) 316–333, hepatitis B surface
antigen (HBsAg) 94–106, and HBsAg 159–171 did not elicit an IFN-γ
response. Supernatants were tested for the presence of IFN-γ by
enzyme-linked immunosorbent assay, as described in Materials and
method. Data represents the average IFN-γ response ± SD of three
mice. hAG, human aggrecan.
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7000To test for peptide cross-reactivity, we established T-cell
lines from DR4-IE transgenic mice that were specific for
hAG 280–292 (hAG280–292 TCL.1 and TCL.2) or
HBsAg 16–33 (HBsAg 16–33 TCL.1). All T-cell lines
were CD4+ and DR4 restricted (data not shown) and
secreted IFN-γ after antigen challenge. As shown in
Table 2, both hAG 280–292 TCL.1 and TCL.2 prolifer-
ated and secreted IFN-γ after being challenged with hAG
280–292, but did not respond to antigen challenge with
either the wild-type HBsAg 16–33 peptide or the altered
HBsAg peptides. Similarly, the HBsAg 16–33 TCL.1
responded to challenge with HBsAg 16–33 but not to the
altered HBsAg peptides or wild-type hAG 280–292.
Thus, TCR recognition of these peptide–DR4 complexes
is highly specific.
Discussion
The role of MHC class II molecules containing the shared
epitope in RA pathogenesis has remained unclear;
however, they are probably involved in binding arthitogenic
peptide antigens for presentation to autoreactive T cells.
In the present study we examined candidate arthritogenic
antigens for predicted T-cell immunogenicity in the context
of DR4 using a model for peptide–MHC affinity, and we
addressed T-cell cross-reactivity based on MHC–
peptide–TCR interactions. We demonstrated that a strong
correlation exists between a peptide’s predicted affinity for
DR4 and its ability to activate IFN-γ secreting T cells from
DR4-IE transgenic mice. We also showed that hAG and
HBsAg may be more immunogenic in the context of DR4
than CII based on the number of predicted T-cell epitopes
found within these antigens. Finally, using T-cell lines spe-
cific for DR4 restricted peptides from HBsAg and hAG,
we showed that TCR recognition of two similar ligands is
highly specific.
The predictive model used here is based on in vitro
binding analysis of peptide–DR4 affinities and was vali-
dated using both random and naturally occurring peptide
sequences [11]. Assignment of a binding score greater
than 2 is an accurate predictor of high affinity peptides.
These encompass approximately 4% of all possible P1
anchored peptides (sequences having the required
aliphatic or aromatic amino acids at the P1 anchor) found
within a protein [11]. On average there are one to three of
these high affinity peptides for every 100 amino acids
within a protein [11]. In comparing the candidate arthrito-
genic antigens to these averages, we found that the hAG
Available online http://arthritis-research.com/content/5/1/R40
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Figure 5
Structural representation of the wild-type peptides human aggrecan
(hAG) 280–292 and hepatitis B surface antigen (HBsAg) 16–33, and
the altered peptides HBsAg L23A and HBsAg L23A/T28R. DR4
pockets P1, P4, and P6 are the major MHC anchor positions (yellow
amino acids), whereas P2, P3, P5, and P8 are solvent exposed and
may contact the TCR (blue amino acids). Amino acids that differ from
hAG 280–292 at TCR contact positions are indicated in red.
Figure 6
Dose dependent proliferative response to the altered peptides
hepatitis B surface antigen (HBsAg) L23A and HBsAg L23A/T28R in
DR4-IE transgenic mice. DR4-IE transgenic mice were immunized with
the indicated peptides and 10 days later their lymph node cells (4 ×
105) were challenged in vitro with the same peptide. Data represents
the average proliferative response ± SEM of six mice.
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HBsAg L23A/T28R first globular and second chondroitin sulfate binding
domains fall within this average (having 2.9 and 3.2 pre-
dicted binders per 100 amino acids, respectively),
whereas the HBsAg shows a higher number (6.2/100)
and CII shows a lower one (0/100). It is of interest to note
that there are more than 25 H-2q restricted T-cell epitopes
for CII in the collagen-induced arthritis susceptible DBA/1
mice [29]. This difference in the number of H-2q versus
DR4 restricted epitopes from CII may help to explain why
these DR4-IE transgenic mice (created on the collagen-
induced arthritis resistant C57BL/6 background) are
resistant to collagen-induced arthritis [30]. The low
number of predicted DR4 binders for CII is probably a
result of its repetitive amino acid sequence, which is nec-
essary for protein folding and function. The G–X1–X2
sequence (where X1 is usually proline and X2 can be any
amino acid except for cysteine) reduces the binding score
of most P1 anchored peptides from CII because glycine is
an inhibitory residue at P4, P6, and P7, whereas proline is
inhibitory at P4 and P9. These constraints allow for few
glycine–proline combinations that will permit interaction
between peptide and the DR4 binding groove.
The immunogenicity of peptides predicted to be high affin-
ity DR4 binders was confirmed using DR4-IE transgenic
mice. Notably, all peptides selected had the required P1
anchor, a noninhibitory residue at the P4 anchor, and
amino acids with variable affinities at P6. T-cell prolifera-
tion and IFN-γ production correlated very well with pre-
dicted MHC affinity, because all peptides with a binding
score greater than 2 elicited a strong recall response in
immunized mice. Two peptides selected with binding
scores below 2 but greater than 0 also caused dose-
dependent T-cell proliferation, one of these being the CII
261–273 sequence. This CII peptide has been shown to
have a relatively high affinity for DR4 and is the dominant
epitope found within CII under DR4 restriction [7,8].
These findings emphasize that, although peptides with
binding scores greater than 2 may be of high affinity, other
sequences falling below this range (>0) can elicit an
immune response.
Although this predictive model may effectively identify
peptides that are capable of activating DR4 restricted T
cells, it must be noted that additional factors influence the
availability of peptides for presentation by MHC class II on
APCs. Included are antigen processing [31,32], HLA-DM
editing [33,34], and post-translational modifications
[35,36], all of which are implicated in autoimmunity. In
addition, some dominant T-cell epitopes have been identi-
fied that have a low affinity for MHC [37], an observation
that increases the complexity of dissecting the immuno-
genicity of a protein antigen. Nevertheless, many dominant
T-cell epitopes from a number of proteins are high affinity
MHC binders and have been predicted as such using this
model [9–11].
Because we were able to identify immunogenic DR4
restricted peptides using this model, we wished to study
the rules that may govern T-cell cross-reactivity and mole-
cular mimicry. Based on MHC–peptide–TCR interactions,
we explored whether two different peptide sequences that
share the properties of binding to DR4 and that presented
similar amino acids to the TCR could activate the same
population of T cells. The two peptides we studied were
the endogenous hAG 280–292 and the exogenous
HBsAg 16–33, which share identical amino acids at the
TCR contact positions P2 and P5. The T-cell lines gener-
ated against these peptides showed a high degree of
specificity because neither peptide was able to induce a
cross-reactive response. Because amino acid substitu-
tions at TCR contact positions can alter recognition
[38–41], we also used peptides that shared most or all
TCR contacts with the hAG 280–292 peptide but main-
tained the MHC anchor positions of HBsAg 16–33.
However, even these were unable to elicit a cross-reactive
response.
The crystal structure of the trimolecular complex shows
that the majority of atomic contacts made by the TCR are
with the MHC itself and not with the solvent exposed
peptide residues [25]. Therefore, amino acid differences
between peptides at the MHC anchoring positions may
Arthritis Research and Therapy    Vol 5 No 1 Hill et al.
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Table 2
Responses of T-cell lines to wild-type and altered peptides
hAG 280–292 TCL.1 hAG 280–292 TCL.2 HBsAg 16–33 TCL.1
Peptide antigen Proliferation (SI) IFN-γ (pg/ml) Proliferation (SI) IFN-γ (pg/ml) Proliferation (SI) IFN-γ (pg/ml)
hAG 280–292 27 10719 49 9827 1 0
HBsAg L23A/T28R 2 327 1 547 1 34
HBsAg L23A 1 260 1 80 1 640
HBsAg 16–33 1 0 1 61 34 7841
Data shown are from a representative experiment showing the T-cell proliferative response in stimulation index (SI) and IFN-γ production after
peptide challenge (10 µg/ml). hAG, human aggrecan; HBsAg, hepatitis B surface antigen.induce subtle changes in the MHC molecule at regions
that are critical for TCR interaction. It has recently been
shown that the width of the DR4 binding groove is influ-
enced by the sequence of the antigenic peptide [28]. This
variable width is dependent on the size of the peptide
side-chain residues that interact with the MHC anchoring
pockets (P1, P4, P6, P7, and P9). Similar MHC class II
conformational changes induced by peptides have been
identified with mAbs [42]. When assessing the peptides
tested in our studies, differences in size were seen at P1
(W-F), P6 (S-I), and P9 (Y-I), and therefore this may have
altered the topology of the MHC at regions recognized by
the TCR.
In addition to the altered MHC contact surface, it has
been shown that a conserved substitution of the peptide
side-chain interacting with P6 can essentially abrogate
T-cell recognition [43]. The substitution of E for D (remov-
ing a single methylene group) within a hemoglobin peptide
bound by I-Ek induced a significant variance in the peptide
main chain between P5 and P8, and changed the rotamer
conformation of the amino acid at P8. Thus, subtle varia-
tions in the antigenic peptide sequence can induce a
number of alterations within the peptide–MHC complex
that may influence TCR recognition.
Conclusion
The experiments presented here show that a strong corre-
lation exists between a peptide’s predicted affinity for
HLA-DRB1*0401 and its ability to activate T cells in DR4-
IE transgenic mice. Although we focused our studies on
HLA-DRB1*0401, the emergence of new predictive matri-
ces such as TEPITOPE (which encompasses predictions
for most DR molecules) [44], utilized in combination with
HLA transgenic mice, should help to determine the role of
MHC class II molecules in the pathogenesis of RA.
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